Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial

The BMJ

Volumn 369, Issue , 2020, Pages

  Tang, Wei ^a   Cao, Zhujun ^a   Han, Mingfeng ^b   Wang, Zhengyan ^c   Chen, Junwen ^c   Sun, Wenjin ^d   Wu, Yaojie ^e   Xiao, Wei ^f   Liu, Shengyong ^g   Chen, Erzhen ^a   Chen, Wei ^a   Wang, Xiongbiao ^h   Yang, Jiuyong ⁱ   Lin, Jun ^j   Zhao, Qingxia ^k   Yan, Youqin ^l   Xie, Zhibin ^g   Li, Dan ^m   Yang, Yaofeng ⁿ   Liu, Leshan ^a   Qu, Jieming ^a   Ning, Guang ^o   Shi, Guochao ^a   Xie, Qing ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b No2 People s Hospital of Fuyang City   (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

^d Central Hospital of Ezhou   (China)

^e Yunmeng People's Hospital   (China)

^f First People's Hospital of Jingzhou City   (China)

^g WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

ⁱ Hubei Space Hospital of Xiaogan   (China)

^j ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^k Sixth People's Hospital of Zhengzhou   (China)

^l Wuhan No7 Hospital   (China)

^m Third People's Hospital of Yichang   (China)

ⁿ Xiaogan First People's Hospital   (China)

^o SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLOID A PROTEIN; HYDROXYCHLOROQUINE; ANTIVIRUS AGENT;

ABDOMINAL DISCOMFORT; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; BLURRED VISION; CHINA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HOSPITAL ADMISSION; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY INJURY; LEUKOPENIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT CARE; POLYDIPSIA; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SINUS BRADYCARDIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; VOMITING; CLINICAL TRIAL; CORONAVIRUS INFECTION; MIDDLE AGED; PANDEMIC; TREATMENT OUTCOME; VIRUS PNEUMONIA;

ADULT; ANTIVIRAL AGENTS; CHINA; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; TREATMENT OUTCOME;

EID: 85084964217     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.m1849     Document Type: Article

References (22)

1. Coronavirus covid-19 global cases by Johns Hopkins CSSE. https://www.arcgis.com/apps/opsdashboard/index. html#/85320e2ea5424dfaaa75ae62e5c06e61.
2. Dyall J, Gross R, Kindrachuk J, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs 2017;77:1935-66. doi:10.1007/s40265-017-0830-1
3. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020. doi:10.1056/ NEJMoa2001282.
4. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. doi:10.1038/s41422-020-0282-0
5. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237.
6. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3. doi:10.5582/bst.2020.01047
7. National Health Commission of the People's Republic of China. Chinese guideline for the management COVID-19 (version 7.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/ s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ ce3e6945832a438eaae415350a8ce964.pdf.
8. US Food and Drug Administration. Emergency Use Authorization. Hydroxychloroquine sulfate health care provider fact sheet. https:// www.fda.gov/media/136534/download.
9. Piller C. "This is insane!" Many scientists lament Trump's embrace of risky malaria drugs for coronavirus. 2020. https://www.sciencemag. org/news/2020/03/insane-many-scientists-lament-trump-sembrace-risky-malaria-drugs-coronavirus#.
10. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015;23:231-69. doi:10.1007/s10787-015-0239-y
11. Baden LR, Rubin EJ. Covid-19\-The search for effective therapy. N Engl J Med 2020:1-2. doi:10.1056/NEJMe2005477.
12. National Health Commission of the People's Republic of China. Chinese guideline for the management covid-19 (version 5.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/ s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ ab6bec7f93e64e7f998d802991203cd6.pdf.
13. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study correction in: BMJ 2020;368:m1295]. BMJ 2020;368:m1091. doi:10.1136/bmj.m1091
14. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443. doi:10.1136/bmj.m1443
15. Harper SA, Bradley JS, Englund JA, et al, Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1003-32. doi:10.1086/598513
16. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentrationresponse relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9. doi:10.1002/art.10307
17. Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 2015;160:799-805.e1. doi:10.1016/j. ajo.2015.07.012
18. van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 2009;31:1737-46. doi:10.1016/j.clinthera.2009.08.009
19. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96. doi:10.1056/ NEJMoa040582
20. Owens RCJr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43:1603-11. doi:10.1086/508873
21. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66. doi:10.1038/s41584-020-0372-x
22. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020. doi:10.1001/jama.2020.3786.